reading satiety threads from 2024 and half of it aged badly
Something I keep coming back to: reading satiety threads from 2024 and half of it aged badly. Bought small deliberately because the evidence base is thin. That felt like the only defensible approach. The honest state of the evidence on this board, since somebody should write it down. Published clinical data exists…
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
phase 3 data will change most of what gets said here
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing.
Agreed, and the combination arms are where the interesting numbers actually live.
nothing here is approved as a standalone product and research material is not for human use
read the combination arms separately from the monotherapy arms
That is preclinical work and the thread is treating it as a human finding.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
independent purity data on this compound is thin